| The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. | leukemia, |
| Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. | leukemia, |
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. | skin, |
| BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. | astrocytomas, |
| RKTG may play a suppressive role in human melanoma that harbors an oncogenic B-Raf mutation via its antagonistic action on B-Raf. | skin, |
| Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. | skin, |
| hyperactivation of the MAPK pathway following activation of an inducible form of oncogenic C-Raf induces a senescence-like proliferation arrest in B-Raf mutant melanoma cells | skin, |
| Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. | skin, |
| These data suggest that regulation of BIM expression by BRAF-->MEK-->ERK signaling is one mechanism by which oncogenic BRAF(V600E) can influence the aberrant physiology of melanoma cells. | skin, |
| BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis | colorectal, |
| Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. | astrocytomas, |
| Oncogenic BRaf (V600E) cooperates with silencing of the Pten tumor suppressor gene to induce metastatic melanoma in mouse models | skin, |
| Oncogenic Braf induces melanocyte senescence and melanoma in mice. | skin, |
| strong inter-relation between DR4 AND DR5 overexpression and presence of oncogenic KRAS/ BRAF mutations in colon cancer. | colorectal, |
| BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. | thyroid, |
| The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. | thyroid, |
| Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. | skin, |
| BRAF and KRAS oncogenes have different transforming capability in colon cancer | colorectal, |
| BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. | colorectal, |
| v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. | sarcoma,ovarian, |